LYA914
LYA914 is an orally active AR/AR-V7 PROTAC degrader. LYA914 targets the proteolytic degradation of the conserved DNA binding domain (DBD) of the androgen receptor (AR). LYA914 exhibits potent antiproliferative effects in Enzalutamide -insensitive/resistant cells. LYA914 inhibits tumor growth in VCaP/LNCaP tumor mouse models. LYA914 can be used to study castration-resistant prostate cancer (CRPC). (Pink: AR-DBD ligand-1: HY-175456, Blue: Thalidomide: HY-14658, Pink + Black: AR-DBD ligand-Linker Conjugate 1: HY-175457, Black: Boc-piperidine-oxopiperidin: HY-175458).
Product Specifications
UNSPSC
12352005
Target
Akt; Androgen Receptor; PROTACs
Related Pathways
PI3K/Akt/mTOR; PROTAC; Vitamin D Related/Nuclear Receptor
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC(N4CCC(CN5CCC(N6CCN(C7=NC(C8=CC=C(F)C(F)=C8OC)=CS7)CC6)CC5)CC4)=C3)=O
Molecular Formula
C38H43F2N7O5S
Molecular Weight
747.85
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cereblon
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lambda Light Chain (MaxLight 750) discontinued
Lentiviral mouse Smap2 shRNA (UAS) - Lentiviral mouse Smap2 shRNA (UAS, RFP) (25)
